Olanzapine treatment after clozapine induced agranulocytosis

Human Psychopharmacology

Volumn 13, Issue 8, 1998, Pages 583-584

  Lokshin, P ^a   Dorfman, P ^b   Shoshani, D ^c   Wimmer, P ^d   Dossenbach, M ^d   Belmaker, R H ^a,e  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b GEHA MENTAL HEALTH CENTER   (Israel)

^c ELI LILLY AND COMPANY   (United States)

^d Lilly Area Medical Center Vienna   (Austria)

^e MENTAL HEALTH CENTER   (Israel)

Author keywords

Agranulocytosis; Clozapine; Olanzapine

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; CASE REPORT; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOSIS;

EID: 0032437934     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(1998120)13:8<583::AID-HUP33>3.0.CO;2-E     Document Type: Article

References (2)

1. Fulton, B. and Goa, K. (1997). Olanzapine - a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs, 53, 281-298.
2. Mendelowitz, A., Stanton, Gerson, L., Alvir, J. and Lieberman, J. (1995). Clozapine-induced agranulocytosis: risk factors, monitoring and management. CNS Drugs, 4, 412-421.